SRRA - シエラ・オンコロジ― （Sierra Oncology Inc.） シエラ・オンコロジ―SRRAのチャート
SRRAの企業情報
| symbol | SRRA |
|---|---|
| 会社名 | Sierra Oncology Inc （シエラ・オンコロジ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Sierra Oncology Inc. formerly ProNAi Therapeutics Inc. is a clinical-stage drug development company. The Company’s lead drug candidate SRA737 is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1) a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141 an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7. シエラ・オンコロジ―はカナダの医薬品メ―カ―。臨床段階で独自のDNA干渉技術(DNAi)により、がん治療薬の開発に従事する。主な薬剤候補は「PNT2258」で、アポト―シスとして知られる細胞死プロセスに関連し、過剰発現するがん遺伝子BCL2をタ―ゲットに開発する。薬剤は静脈点滴により体内へ取り込まれる。本社はバンク―バ―。 Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact. |
| 本社所在地 | 2150 - 885 West Georgia Street Vancouver British Columbia V6C 3E8 CAN |
| 代表者氏名 | Donald R. Parfet ドナルドRパーフェット |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 604-558-6536 |
| 設立年月日 | 37742 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 57人 |
| url | www.sierraoncology.com |
| nasdaq_url | https://www.nasdaq.com/symbol/srra |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -45.49600 |
| 終値（lastsale） | 1.659 |
| 時価総額（marketcap） | 123336996.279 |
| 時価総額 | 時価総額（百万ドル） 131.58920 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6.16420 |
| 当期純利益 | 当期純利益（百万ドル） -36.87900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Sierra Oncology Inc revenues was not reported. Net loss increased 10% to $23.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.46 to -$0.35. |
SRRAのテクニカル分析
SRRAのニュース
GlaxoSmithKline completes acquisition of Sierra Oncology 2022/07/01 14:54:40 Seeking Alpha
GlaxoSmithKline (GSK) has completed its acquisition of Sierra Oncology after the latter''s shareholders approved the deal on June 29.
GSK completes acquisition of Sierra Oncology 2022/07/01 14:34:37 GlaxoSmithKline Pharmaceuticals
GSK announced it has completed the acquisition of Sierra Oncology, a California-based biopharmaceutical company.
Astrazeneca PLC – Consensus Indicates Potential 11.4% Upside 2022/06/27 08:22:53 DirectorsTalk
Astrazeneca PLC found using ticker (AZN) have now 5 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 80 and 59 with a mean TP of 71.8. Given that the stocks previous close was at 64.45 this indicates there is a potential upside of 11.4%. The 50 day MA is 65.02 and the 200 day MA is 61.05. The market cap for the company is $207,319m. You can visit the company''s website by visiting: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $230,962m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration 2022/06/17 11:00:00 Kwhen Finance
Sierra Oncology Inc Shares Approach 52-Week High - Market Mover 2022/06/17 00:00:00 Kwhen Finance
Sierra Oncology Inc (SRRA) shares closed today at 0.5% below its 52 week high of $55.17, giving the company a market cap of $1B. The stock is currently up 152.5% year-to-date, up 199.3% over the past 12 months, and up 20.4% over the past five years. This week, the Dow Jones Industrial Average fell 4.8%, and the S&P 500 fell 5.7%. Trading Activity Trading volume this week was 16.3% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 0.0% lower than its 5-day moving average, 0.1% higher than its 20-day moving average, and 24.3% higher than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1320.8% The company's stock price performance over the past 12 months beats the peer average by -1254.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
GlaxoSmithKline completes acquisition of Sierra Oncology 2022/07/01 14:54:40 Seeking Alpha
GlaxoSmithKline (GSK) has completed its acquisition of Sierra Oncology after the latter''s shareholders approved the deal on June 29.
GSK completes acquisition of Sierra Oncology 2022/07/01 14:34:37 GlaxoSmithKline Pharmaceuticals
GSK announced it has completed the acquisition of Sierra Oncology, a California-based biopharmaceutical company.
Astrazeneca PLC – Consensus Indicates Potential 11.4% Upside 2022/06/27 08:22:53 DirectorsTalk
Astrazeneca PLC found using ticker (AZN) have now 5 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 80 and 59 with a mean TP of 71.8. Given that the stocks previous close was at 64.45 this indicates there is a potential upside of 11.4%. The 50 day MA is 65.02 and the 200 day MA is 61.05. The market cap for the company is $207,319m. You can visit the company''s website by visiting: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $230,962m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration 2022/06/17 11:00:00 Kwhen Finance
Sierra Oncology Inc Shares Approach 52-Week High - Market Mover 2022/06/17 00:00:00 Kwhen Finance
Sierra Oncology Inc (SRRA) shares closed today at 0.5% below its 52 week high of $55.17, giving the company a market cap of $1B. The stock is currently up 152.5% year-to-date, up 199.3% over the past 12 months, and up 20.4% over the past five years. This week, the Dow Jones Industrial Average fell 4.8%, and the S&P 500 fell 5.7%. Trading Activity Trading volume this week was 16.3% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 0.0% lower than its 5-day moving average, 0.1% higher than its 20-day moving average, and 24.3% higher than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1320.8% The company's stock price performance over the past 12 months beats the peer average by -1254.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
GlaxoSmithKline completes acquisition of Sierra Oncology 2022/07/01 14:54:40 Seeking Alpha
GlaxoSmithKline (GSK) has completed its acquisition of Sierra Oncology after the latter''s shareholders approved the deal on June 29.
GSK completes acquisition of Sierra Oncology 2022/07/01 14:34:37 GlaxoSmithKline Pharmaceuticals
GSK announced it has completed the acquisition of Sierra Oncology, a California-based biopharmaceutical company.
Astrazeneca PLC – Consensus Indicates Potential 11.4% Upside 2022/06/27 08:22:53 DirectorsTalk
Astrazeneca PLC found using ticker (AZN) have now 5 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 80 and 59 with a mean TP of 71.8. Given that the stocks previous close was at 64.45 this indicates there is a potential upside of 11.4%. The 50 day MA is 65.02 and the 200 day MA is 61.05. The market cap for the company is $207,319m. You can visit the company''s website by visiting: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $230,962m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration 2022/06/17 11:00:00 Kwhen Finance
Sierra Oncology Inc Shares Approach 52-Week High - Market Mover 2022/06/17 00:00:00 Kwhen Finance
Sierra Oncology Inc (SRRA) shares closed today at 0.5% below its 52 week high of $55.17, giving the company a market cap of $1B. The stock is currently up 152.5% year-to-date, up 199.3% over the past 12 months, and up 20.4% over the past five years. This week, the Dow Jones Industrial Average fell 4.8%, and the S&P 500 fell 5.7%. Trading Activity Trading volume this week was 16.3% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 0.0% lower than its 5-day moving average, 0.1% higher than its 20-day moving average, and 24.3% higher than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1320.8% The company's stock price performance over the past 12 months beats the peer average by -1254.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.